At the news
? BULLISHIMPACT 7/10 6-K filed Sep 1, 2026 at 20:30 ET
Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting. The company also aligned with the FDA on an NDA pathway that, if approved, would support new product reimbursement and broaden patient access. This is a significant clinical milestone that could expand Telix's addressable market substantially if the study meets its primary objectives.
- Completed enrollment of 350 patients in the Phase 3 BiPASS study
- Aligned with FDA on an NDA pathway for BiPASS that would support new product reimbursement
- BiPASS is the first registrational study of 68Ga-PSMA-PET imaging in the pre-biopsy setting
- Prior PRIMARY and PRIMARY2 studies demonstrated combining PSMA-PET with MRI can reduce unnecessary biopsies by almost 50%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access